Get the Stockscreener App
2.4699
4.41%
0.1099
Immunitybio Inc stock is traded at $2.4699, with a volume of 8.52M.
It is up +4.41% in the last 24 hours and down -5.23% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.36
Open:
$2.38
24h Volume:
8.52M
Relative Volume:
0.92
Market Cap:
$2.33B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.5463
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
-2.61%
1M Performance:
-5.23%
6M Performance:
-6.31%
1Y Performance:
-32.49%
1-Day Range:
$2.375
$2.50
1-Week Range:
$2.36
$2.61
52-Week Range:
$1.83
$7.48
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
2.47 | 2.23B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.62 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.57 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.99 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
803.71 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
330.86 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-06-25 | Initiated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | BTIG Research | Buy |
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Can machine learning forecast ImmunityBio Inc. recoveryPortfolio Update Summary & AI Forecast for Swing Trade Picks - newser.com
ImmunityBio Inc. stock trend outlook and recovery path2025 Top Gainers & Fast Moving Stock Trade Plans - newser.com
Will ImmunityBio Inc. rebound enough to break evenBear Alert & Community Consensus Picks - newser.com
Is ImmunityBio Inc. stock a buy on dipsJuly 2025 WrapUp & Community Trade Idea Sharing Platform - newser.com
How to recover losses in ImmunityBio Inc. stockJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com
Will ImmunityBio Inc. stock benefit from infrastructure spendingPortfolio Return Report & Low Drawdown Trading Strategies - newser.com
Published on: 2025-10-11 12:10:43 - earlytimes.in
ImmunityBio, Inc. (IBRX) Reports Strong Q2 Growth, Eyes Lung Cancer and NMIBC Expansion - MSN
Why ImmunityBio Inc. (26CA) stock is a strong analyst pick2025 Top Decliners & Daily Profit Focused Stock Screening - newser.com
Will EnGene Join The Ranks Of Merck, Ferring, And ImmunityBio In Bladder Cancer Treatment? - RTTNews
Will ImmunityBio Inc. stock outperform tech sector in 2025Quarterly Performance Summary & Precise Swing Trade Alerts - newser.com
How ImmunityBio Inc. stock reacts to job market data2025 Momentum Check & Safe Investment Capital Preservation Plans - newser.com
Real time social sentiment graph for ImmunityBio Inc.2025 Pullback Review & Accurate Intraday Trading Signals - newser.com
Evaluating ImmunityBio Inc. with trendline analysis2025 Major Catalysts & Growth Oriented Trading Recommendations - newser.com
Is ImmunityBio Inc. (26CA) stock prepared for digital transitionJuly 2025 Technicals & Smart Allocation Stock Tips - newser.com
ImmunityBio Inc. stock retracement – recovery analysis2025 Investor Takeaways & AI Enhanced Trading Signals - newser.com
ANKTIVA Reimbursement Gains and UK Approval Might Change The Case For Investing In ImmunityBio (IBRX) - Sahm
ImmunityBio, Inc. (NASDAQ:IBRX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
What Went Wrong With ImmunityBio’s Executives Claims — and How Investors Could Still Win - TradingView
ImmunityBio: A Small Bet Is Warranted (NASDAQ:IBRX) - Seeking Alpha
NMIBC Market to Experience Notable Growth in Forecast Span - openPR.com
Short interest data insights for ImmunityBio Inc.Earnings Growth Report & Technical Pattern Recognition Alerts - newser.com
Does ImmunityBio Inc. show high probability of reboundJuly 2025 Pullbacks & Stepwise Trade Signal Implementation - newser.com
What MACD and RSI say about ImmunityBio Inc.July 2025 Retail & Weekly High Return Stock Opportunities - newser.com
ImmunityBio (IBRX): Revisiting Valuation After ANKTIVA’s Regulatory Wins and New Growth Initiatives - Sahm
How high can ImmunityBio Inc. stock go2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
Wall Street Bullish on ImmunityBio (IBRX) Since the Announcement of New Findings From QUILT-3.055 Study - MSN
ImmunityBio’s (IBRX) ANKTIVA Shows Survival Gains in Lung Cancer Patients - MSN
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
| Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
| Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
| Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
| Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
| Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
| Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
| LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
1.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):